Search Result

Results for "

URAT1/GLUT9 inhibotor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	URAT1 (26) Apoptosis (1) Cholinesterase (ChE) (1) GLUT (4) MMP (1) OAT (4) PDGFR (1) Reactive Oxygen Species (1) Reverse Transcriptase (1) Xanthine Oxidase (4)
By Research Areas:	Cancer (2) Cardiovascular Disease (2) Infection (2) Inflammation/Immunology (11) Metabolic Disease (16) Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Targets Recommended: URAT1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-144305

KPH2f	URAT1 GLUT	Infection
KPH2f is a safe, orally active, and effective dual *URAT1/GLUT9* inhibitor with IC₅₀s of 0.24 μM and 9.37 μM for URAT1 and GLUT9, respectively. KPH2f shows little effects on OAT1 and ABCG2 (IC₅₀=32.14 and 26.74 μM) ^[1].

HY-151432

URAT1 inhibitor 3	URAT1	Inflammation/Immunology
URAT1 inhibitor 3 is a potent, orally active, selective *URAT1* inhibitor with an IC₅₀ value of 0.8 nM. URAT1 inhibitor 3 has urate-lowering efficacy. URAT1 inhibitor 3 can be used in research of gout and hyperuricemi ^[1].

HY-153971

URAT1 inhibitor 8	URAT1	Metabolic Disease
URAT1 inhibitor 8 (example 247) is a potent *URAT1* inhibitor, with an IC₅₀ of 0.001 μM. URAT1 inhibitor 8 can be used for gout research ^[1].

HY-114309

URAT1 inhibitor 1	URAT1	Inflammation/Immunology
URAT1 inhibitor 1 (1g) is a uric acid transporter 1 (URAT1) inhibitor, with an IC₅₀ of 32 nM. URAT1 inhibitor 1 has potential to treat hyperuricemia associated with gout ^[1].

HY-158056

URAT1/GLUT9-IN-1	GLUT URAT1	Metabolic Disease
URAT1/GLUT9-IN-1 (compound 29) can inhibit both uric acid transporter 1 (URAT1) (IC₅₀=2.01 μM) and glucose transporter 9 (GLUT9) (IC₅₀=18.21 μM). URAT1/GLUT9-IN-1 exhibits favorable pharmacokinetic properties and oral bioavailability. URAT1/GLUT9-IN-1 can be uesd for gout and hyperuricemia research ^[1].

HY-143906

URAT1 inhibitor 2	URAT1	Inflammation/Immunology
URAT1 inhibitor 2 is an orally active and potent *URAT1* and CYP isozyme inhibitor, with IC₅₀ values of 1.36 μM, 16.97 μM, 5.22 μM for URAT1-mediated ¹⁴C-UA uptake, CYP1A2 and CYP2C9, respectively. URAT1 inhibitor 2 is a promising agent candidate in the study of hyperuricemia and gout ^[1].

HY-163431

URAT1 inhibitor 10	URAT1	Inflammation/Immunology
URAT1 inhibitor 10 (Compound 23a) is a *URAT1* inhibitor. URAT1 inhibitor 10 has oral efficacy and low cytotoxicity. URAT1 inhibitor 10 has high selectivity for *OAT1* ^[1].

HY-153706

URAT1 inhibitor 5	URAT1	Cardiovascular Disease Metabolic Disease
URAT1 inhibitor 5 (compound 16) is a potent *URAT1* inhibitor. URAT1 inhibitor 5 can be used in research of hyperuricemia ^[1].

HY-153970

URAT1 inhibitor 7	URAT1	Inflammation/Immunology
URAT1 inhibitor 7 (compound 10f) is a potent *URAT1* inhibitor, with an IC₅₀ of 12 nM. URAT1 inhibitor 7 exhibits microsomal stability (HLM <13 µL/min/mg). URAT1 inhibitor 7 also inhibits *CYP2C9, with an IC₅₀* of 4.2 μM. URAT1 inhibitor 7 can be used for gout research ^[1].

HY-160265

URAT1 inhibitor 9	URAT1	Inflammation/Immunology
URAT1 inhibitor 9 (Compound 24) is an *URAT1* inhibitor that can be used in the study of gout or hyperuricemia ^[1].

HY-153969

URAT1 inhibitor 6	URAT1	Inflammation/Immunology
URAT1 inhibitor 6 (Compound 1h) is a potent *URAT1* inhibitor (IC₅₀: 35 nM for hURAT1). URAT1 inhibitor 6 is 200- and 8-fold more potent than parent Lesinurad (HY-15258) and Benzbromarone (HY-B1135). URAT1 inhibitor 6 can be used for research of inflammation ^[1].

HY-152033

URAT1 inhibitor 4	URAT1 GLUT	Metabolic Disease
URAT1 inhibitor 4, a Lesinurad derivative, is a potent and orally active *URAT1* inhibitor with an IC₅₀ of 7.56 μM. URAT1 inhibitor 4 has higher in vivo urate-lowering efficacy than Lesinurad (HY-15258) ^[1].

HY-168740

URAT1 inhibitor 11	URAT1	Metabolic Disease
URAT1 inhibitor 11 (Compound 7) is a *URAT1* inhibitor with an IC₅₀ value of 0.18 μM. URAT1 inhibitor 11 exhibits potent hypouricemic effects in hyperuricemic zebrafish induced by Potassium oxonate (HY-17511) and Xanthine sodium salt (HY-W017389) ^[1].

HY-153972

URAT1&XO inhibitor 2	URAT1 Xanthine Oxidase	Metabolic Disease Inflammation/Immunology
URAT1&XO inhibitor 2 (Compound BDEO) is a dual inhibitor of xanthine oxidase and *URAT1, with IC₅₀* of 3.3 μM for xanthine oxidase. URAT1&XO inhibitor 2 blocks uptake of uric acid in HEK293 cells expressing URAT1, with a K_i value of 0.145 μM. URAT1&XO inhibitor 2 decreases serum urate level and uric acid excretion in hyperuricemic mice. URAT1&XO inhibitor 2 can be used for research of hyperuricemia ^[1].

HY-153968

URAT1&XO inhibitor 1	Xanthine Oxidase URAT1	Metabolic Disease
URAT1&XO inhibitor 1 (compound 29) is a dual inhibitor of both URAT1 (IC₅₀=~10 μM) and Xanthine Oxidase (IC₅₀=1.01 μM). URAT1&XO inhibitor 1 results hypouricemic effect in potassium oxonate-induced hyperuricemia rat model. URAT1&XO inhibitor 1 is used for hyperuricemia research ^[1].

HY-159581

URAT1&XO inhibitor 3	URAT1	Others
URAT1&XO inhibitor 3 (compound 27) is an orally active anti-gout agent targeting XO (IC₅₀: 35 nM) and *URAT1* (IC₅₀: 31 nM). URAT1&XO inhibitor 3 has good pharmacological and pharmacokinetic (PK) characteristics and in vivo safety ^[1].

HY-157306

HC-1310	URAT1	Metabolic Disease
HC-1310 URAT1 Inhibitor (Compound 83) is a potent *URAT1* inhibitor and can be used for research on hyperuricemia and gout ^[1].

HY-161523

*XOR/URAT1-IN-1*	Xanthine Oxidase URAT1	Metabolic Disease
XOR/URAT1-IN-1 (Compound II15) is a dual inhibitor for xanthine oxidoreductase (XOR) and uric acid transporter 1 (URAT1), with IC₅₀ of 6 nM and 12.9 μM. XOR/URAT1-IN-1 lowers the levels of uric acid in Potassium oxonate (HY-17511)/Hypoxanthine (HY-N0091)-induced acute hyperuricemia mouse model ^[1].

HY-101439

JTT-552	URAT1	Others
JTT-552 is a compound targeting URAT1 with activity in inhibiting hyperuricemia and gout.

HY-16733

Verinurad RDEA3170	URAT1	Metabolic Disease
Verinurad (RDEA3170) is a highly potent and specific *URAT1* inhibitor with an IC₅₀ of 25 nM ^[1].

HY-15258

Lesinurad 2 Publications Verification RDEA594	OAT URAT1	Metabolic Disease
Lesinurad is a *URAT1* and OAT inhibitor, is determined to be a substrate for the kidney transporters *OAT1* and OAT3 with K_m values of 0.85 and 2 µM, respectively.

HY-15258A

Lesinurad sodium 2 Publications Verification RDEA-594 sodium	OAT URAT1	Metabolic Disease
Lesinurad sodium is a *URAT1* and OAT inhibitor, is determined to be a substrate for the kidney transporters *OAT1* and OAT3 with K_m values of 0.85 and 2 μM, respectively.

HY-162829

hURAT1 inhibitor 1	URAT1 GLUT	Metabolic Disease
hURAT1 inhibitor 1 (compound 27b) is an isomarine-based, orally active dual *hURAT1/GLUT9* inhibitor with IC₅₀s of 0.16 μM and 4.47 μM, respectively, and has anti-hyperuricemia effects. hURAT1 inhibitor 1 showed significant uric acid-lowering activity in a hyperuricemia mouse model (10 mg/kg dose). hURAT1 inhibitor 1 had no significant in vitro cytotoxicity or in vivo hepatotoxicity and showed good PK characteristics ^[1].

HY-116694

Digallic acid	Apoptosis Reactive Oxygen Species Reverse Transcriptase Xanthine Oxidase URAT1	Infection Metabolic Disease Inflammation/Immunology Cancer
Digallic acid is an antioxidant, antimutagenic, antigenotoxic, and anti-hyperuricemic compound. Digallic acid is a reverse transcriptase and XOD, *URAT1* (IC₅₀: 5.34 μM) inhibitor. Digallic acid scavenges DPPH· and O2·− radicals. Digallic acid induces apoptosis. Digallic acid can be isolated from the fruits of Pistascia lentiscus ^[1] .

HY-111345

Epaminurad UR-1102; URC-102	OAT URAT1	Metabolic Disease Inflammation/Immunology
Epaminurad (UR-1102) is an orally active, potent and selective *URAT1* (urate transporter 1) inhibitor, with a K_i of 0.057 μM. Epaminurad quite modestly inhibits *OAT1* and OAT3 (organic anion transporter). Epaminurad is a uricosuric agent. Epaminurad can be used for gout and hyperuricemia research ^[1].

HY-111345A

Epaminurad hydrochloride UR-1102 hydrochloride; URC-102 hydrochloride	OAT URAT1	Metabolic Disease Inflammation/Immunology
Epaminurad (UR-1102) hydrochloride is an orally active, potent and selective *URAT1* (urate transporter 1) inhibitor, with a K_i of 0.057 μM. Epaminurad hydrochloride quite modestly inhibits *OAT1* and OAT3 (organic anion transporter). Epaminurad hydrochloride is a uricosuric agent. Epaminurad hydrochloride can be used for gout and hyperuricemia research ^[1].

HY-116111

AG 370	PDGFR	Cardiovascular Disease
AG 370, an indole tyrphostin, is a potent PDGF-induced mitogenesis inhibotor (IC₅₀ of 20 μM). AG 370 displays weak inhibition of the EGF receptor ^[1].

HY-122957

Huperzine C	Cholinesterase (ChE)	Neurological Disease
Huperzine C is an alkaloid isolated from Huperzia serrate. Huperzine C is an acetylcholinesterase (AChE) inhibotor, with an IC₅₀ of 0.6 μM. Huperzine C can be used for the research of Alzheimer’s disease ^[1] .

HY-161284

MMP-9/10-IN-1	MMP	Cancer
MMP-9/10-IN-1 (Compound 6b) is a potent dual *MMP-9/10* Inhibotor with IC₅₀s of 0.076 and 0.139 μM against NSCLC and A549 cells, respectively. MMP-9/10-IN-1 has anti-invasive and anti-angiogenic activities when in combination with Sorafenib (HY-10201) ^[1].

Digallic acid	Structural Classification Pistacia lentiscus var. Chia Source classification Phenols Polyphenols Plants Anacardiaceae	Apoptosis Reactive Oxygen Species Reverse Transcriptase Xanthine Oxidase URAT1
Digallic acid is an antioxidant, antimutagenic, antigenotoxic, and anti-hyperuricemic compound. Digallic acid is a reverse transcriptase and XOD, *URAT1* (IC₅₀: 5.34 μM) inhibitor. Digallic acid scavenges DPPH· and O2·− radicals. Digallic acid induces apoptosis. Digallic acid can be isolated from the fruits of Pistascia lentiscus ^[1] .

Huperzine C	Lycopodiaceae Alkaloids Lycopodium serratum Thunb． Source classification Plants	Cholinesterase (ChE)
Huperzine C is an alkaloid isolated from Huperzia serrate. Huperzine C is an acetylcholinesterase (AChE) inhibotor, with an IC₅₀ of 0.6 μM. Huperzine C can be used for the research of Alzheimer’s disease ^[1] .

Cat. No.	Compare	Product Name	Species	Source

HY-P703382

	SLC22A12 Protein, Human (HEK293) OATL4; URAT1	Human	HEK293
	SLC22A12 Protein, Human (HEK293) is the recombinant human-derived SLC22A12, expressed by HEK293 , with tag Free labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

URAT1/GLUT9 inhibotor

Inhibitors & Agonists

NaturalProducts

Recombinant Proteins

Natural
Products